June 2006 Cover
|
 |
Boosted atazanavir (Reyataz) suppresses viral load as effectively as lopinavir/ritonavir (Kaletra) in multidrug-resistant patients, while causing fewer adverse effects, according to 96-week results from BMS Study 045.
The randomized, open-label study compared a once-daily regimen of atazanavir + ritonavir (Norvir) + tenofovir (Viread) + an NRTI to a twice-daily regimen of lopinavir/ritonavir + tenofovir + an NRTI in HIV-infected patients
who had experienced virologic failure on at least two HAART regimens.
The researchers found that the two regimens had a similarly profound, long-term impact on viral load, but differed in toxicity: Boosted atazanavir appeared to cause far fewer gastrointestinal problems
(particularly diarrhea), and had a significantly more beneficial impact on lipid levels.
Editor's Note: from theBodyPro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
